RU2019128204A - Белки, связывающиеся с psma, nkg2d и cd16 - Google Patents

Белки, связывающиеся с psma, nkg2d и cd16 Download PDF

Info

Publication number
RU2019128204A
RU2019128204A RU2019128204A RU2019128204A RU2019128204A RU 2019128204 A RU2019128204 A RU 2019128204A RU 2019128204 A RU2019128204 A RU 2019128204A RU 2019128204 A RU2019128204 A RU 2019128204A RU 2019128204 A RU2019128204 A RU 2019128204A
Authority
RU
Russia
Prior art keywords
seq
amino acid
variable domain
acid sequence
binding site
Prior art date
Application number
RU2019128204A
Other languages
English (en)
Russian (ru)
Other versions
RU2019128204A3 (enExample
Inventor
Грегори П. ЧАН
Энн Ф. ЧЕУНГ
Уилльям Хани
Брэдли М. ЛУНДЕ
Бьянка Принц
Original Assignee
Драгонфлай Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Драгонфлай Терапьютикс, Инк. filed Critical Драгонфлай Терапьютикс, Инк.
Publication of RU2019128204A publication Critical patent/RU2019128204A/ru
Publication of RU2019128204A3 publication Critical patent/RU2019128204A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2019128204A 2017-02-10 2018-02-10 Белки, связывающиеся с psma, nkg2d и cd16 RU2019128204A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762457785P 2017-02-10 2017-02-10
US62/457,785 2017-02-10
PCT/US2018/017718 WO2018148610A1 (en) 2017-02-10 2018-02-10 Proteins binding psma, nkg2d and cd16

Publications (2)

Publication Number Publication Date
RU2019128204A true RU2019128204A (ru) 2021-03-10
RU2019128204A3 RU2019128204A3 (enExample) 2021-07-16

Family

ID=63107819

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019128204A RU2019128204A (ru) 2017-02-10 2018-02-10 Белки, связывающиеся с psma, nkg2d и cd16

Country Status (13)

Country Link
US (1) US20200024353A1 (enExample)
EP (1) EP3579878A4 (enExample)
JP (2) JP2020507577A (enExample)
KR (1) KR20190120770A (enExample)
CN (1) CN110913902A (enExample)
AU (1) AU2018217834A1 (enExample)
BR (1) BR112019016553A2 (enExample)
CA (1) CA3053275A1 (enExample)
IL (1) IL268574A (enExample)
MX (1) MX2019009541A (enExample)
RU (1) RU2019128204A (enExample)
SG (1) SG11201907271PA (enExample)
WO (1) WO2018148610A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3579848T3 (da) 2017-02-08 2025-01-20 Dragonfly Therapeutics Inc Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
SG11202007579TA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
EP3833385A4 (en) 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CN115836088A (zh) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
CN117881702A (zh) * 2021-08-03 2024-04-12 山东先声生物制药有限公司 一种cd16抗体及其应用
WO2023011650A1 (zh) * 2021-08-06 2023-02-09 甘李药业股份有限公司 一种多特异性抗体及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001071005A2 (en) * 2000-03-24 2001-09-27 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US6455712B1 (en) * 2000-12-13 2002-09-24 Shell Oil Company Preparation of oxirane compounds
WO2007002905A1 (en) * 2005-06-29 2007-01-04 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
US20090226466A1 (en) * 2005-11-03 2009-09-10 Sherman Fong Therapeutic anti-her2 antibody fusion polypeptides
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
DK2222706T4 (en) * 2007-12-14 2016-11-21 Novo Nordisk As Antibodies that bind to NKG2D and its use
EP2419451A4 (en) * 2009-04-14 2012-11-14 Proscan Rx Pharma Inc ANTIBODIES DIRECTED AGAINST THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX336323B (es) * 2010-04-15 2016-01-15 Genentech Inc Anticuerpos de anti-poliubiquitina y metodos de uso.
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
WO2013022848A1 (en) * 2011-08-05 2013-02-14 Genentech, Inc. Anti-polyubiquitin antibodies and methods of use
WO2014179363A1 (en) * 2013-04-29 2014-11-06 Adimab, Llc Polyspecificity reagents, methods for their preparation and use
SG10201913680PA (en) * 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
MX2017006016A (es) * 2014-11-11 2017-06-19 Amunix Operating Inc Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.
EP3243837A4 (en) * 2015-01-08 2018-12-05 Kyowa Hakko Kirin Co., Ltd. Bispecific antibody binding to trailr2 and psma
CA2973720A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
EP3258967A4 (en) * 2015-02-20 2018-10-03 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
WO2016135041A1 (en) * 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2016164308A1 (en) * 2015-04-06 2016-10-13 Subdomain, Llc De novo binding domain containing polypeptides and uses thereof
EP3313876B1 (en) * 2015-06-23 2025-01-22 Innate Pharma Multispecific antigen binding proteins

Also Published As

Publication number Publication date
IL268574A (en) 2019-09-26
CN110913902A (zh) 2020-03-24
CA3053275A1 (en) 2018-08-16
US20200024353A1 (en) 2020-01-23
JP2020507577A (ja) 2020-03-12
JP2022105121A (ja) 2022-07-12
AU2018217834A1 (en) 2019-08-22
BR112019016553A2 (pt) 2020-03-31
RU2019128204A3 (enExample) 2021-07-16
WO2018148610A1 (en) 2018-08-16
MX2019009541A (es) 2019-12-16
KR20190120770A (ko) 2019-10-24
SG11201907271PA (en) 2019-09-27
EP3579878A1 (en) 2019-12-18
EP3579878A4 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
JP2023052214A5 (enExample)
JP2021098733A5 (enExample)
RU2019129511A (ru) Белки, связывающие gd2, nkg2d и cd16
JP2021035388A5 (ja) Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン−１８．２を標的にする多重特異性結合タンパク質
RU2021110369A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
JP2021098732A5 (enExample)
JP2020521448A5 (enExample)
JP2020510653A5 (ja) Ｃｅａを標的にする多重特異性結合タンパク質
JP2020507577A5 (enExample)
JP2020522473A5 (enExample)
JP2020531438A5 (ja) Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質
JP2020508997A5 (enExample)
JP2020507328A5 (enExample)
FI3582806T3 (fi) Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja
JP2022551969A5 (enExample)
RU2019128134A (ru) Антитело против gprc5d и молекула, содержащая антитело
FI3749346T3 (fi) Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
JP2023106433A5 (enExample)
JP2020522474A5 (enExample)
JP2020533311A5 (ja) ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質
JP2021512630A5 (enExample)
JP2021523140A5 (enExample)
RU2013142600A (ru) Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
JP2020510646A5 (enExample)
RU2020111554A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген